"In lay terminology, the Company is looking to compile more supporting data as it conducts more experiments. This is similar to fine tuning a race car engine before the race. We need to understand the various aspects that lead to the best performance," stated David Koos, Chairman of the Board of Directors and Chief Executive Officer of Regen BioPharma, Inc.
The preliminary experiments revealed that administration of Regen's proprietary compounds RG-NA01, RG-NI01 and RG-NI02 prevented cells of the immune system from producing inflammatory factors (e.g.: interleukin-2, interferon-gamma, tumor necrosis factor-alpha and, importantly, interleukin-17a). These factors are critically involved in the immune response found in autoimmune diseases such as rheumatoid arthritis and psoriasis.
The next step in developing small molecule drugs that target NR2F6 is to optimize the compounds for efficacy. The Company is looking to maximize the ability to either inhibit NR2F6 or stimulate it depending on the desired out come. The goal is to have a series of compounds that can modulate the immune system up (stimulate) or down (inhibit). Being able to modulate the immune system means you can treat autoimmune diseases and cancers, similar to turning a light switch either off or on depending upon whether you wish to treat arthritis ("light switch" is on) or cancer ("light switch" is off).
"We are currently at a point of concentrating on the aspects of these compounds that make them more powerful in treating autoimmune diseases and cancer. Also, we are looking for a high level of predictability in treatment out comes. Once we have achieved these goals, we will focus on moving forward towards clinical trials," said Harry M. Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. "Our data are solid, but we need to move it to the next stages of development to be sure we have compounds that will be able to move forward into the clinic. This includes answering some basic questions such as specificity (do our molecules only bind to NR2F6 or do they also bind to other proteins?), mechanisms of action (how exactly do these molecules turn NR2F6 on and off?) and other similar questions. This is a matter of following a well-known set of procedures to do these tests as all small molecule drugs must have these questions answered."
"Regen BioPharma's management team believes in both the social and financial value of its small molecule program involving NR2F6. Since January 2015, we have raised more than $3.2 million to move things forward. This money has come from high net worth individuals that believe in the merits of the Company's research. Looking ahead, we anticipate a combination of continued investment by high net worth individuals, transitioning to partnering arrangements with one or more larger pharmaceutical companies to assist us with clearing clinical trials," stated the Company's Chairman and CEO.
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is focused on gene silencing therapy and small molecule therapies for treating cancer, along with developing stem cell treatments for aplastic anemia and disorders of the bone marrow. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
SOURCE Regen BioPharma, Inc.